Sanofi-Aventis Sues Synthon Over Generic Ambien
The leading drug maker claims Synthon Pharmaceuticals filed a new drug application with the U.S. drug agency for a generic version of Ambien, in direct violation of its patent.
In the complaint filed Monday in the North Carolina federal court, lawyers for Sanofi-Aventis called for a permanent injunction on Synthon manufacturing or marketing its version in the U.S.
It also seeks a moratorium on approval for...
To view the full article, register now.